A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review)
The use of 5α-reductase inhibitors (5α-RIs) as prostate cancer chemoprevention agents is controversial. Two large randomized trials, the Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial, have both shown a decreased incidence of prostat...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
D.A. Spandidos
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156162/ |